Clinical Trial Update: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) [Phase 2]

View source ↗

Summary

A Phase 2 feasibility trial of glofitamab for diffuse large B-cell lymphoma using interim FDG PET and ctDNA to optimize initial therapy; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Glofitamab (Columvi) (glofitamab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING